
Outcomes of Positive and Suspicious Findings in Clinical Computed Tomography Lung Cancer Screening and the Road Ahead
Author(s) -
Shawn M. Regis,
Andrea Borondy Kitts,
Andrea B. McKee,
Kimberly Rieger-Christ,
Jacob Sands,
Jalil Afnan,
Brian Mckee
Publication year - 2022
Publication title -
annals of the american thoracic society
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.035
H-Index - 114
eISSN - 2329-6933
pISSN - 2325-6621
DOI - 10.1513/annalsats.202106-733oc
Subject(s) - medicine , lung cancer , lung cancer screening , radiology , computed tomography , cancer , retrospective cohort study , lung , solitary pulmonary nodule , clinical practice , family medicine
Rationale: Future optimization of computed tomography (CT) lung cancer screening (CTLS) algorithms will depend on clinical outcomes data. Objectives: To report the outcomes of positive and suspicious findings in a clinical CTLS program. Methods: We retrospectively reviewed results for patients from our institution undergoing lung cancer screening from January 2012 through December 2018, with follow-up through December 2019. All exams were retrospectively rescored using Lung-RADS v1.1 (LR). Metrics assessed included positive, probably benign, and suspicious exam rates, frequency/nature of care escalation, and lung cancer detection rates after a positive, probably benign, and suspicious exam result and overall. We calculated time required to resolve suspicious exams as malignant or benign. Results were broken down by subcategories, reason for positive/suspicious designation, and screening round. Results: During the study period 4,301 individuals underwent a total of 10,897 exams. The number of positive (13.9%), suspicious (5.5%), and significant incidental (6.4%) findings was significantly higher at baseline screening. Cancer detection and false-positive rates were 2.0% and 12.3% at baseline versus 1.3% and 5.1% across subsequent screening rounds, respectively. Baseline solid nodule(s) 6 to <8 mm were the only probably benign findings resulting in lung cancer detection within 12 months. New solid nodules 6 to <8 mm were the only LR category 4A (LR4A) findings falling within the LR predicted cancer detection range of 5-15% (12.8%). 38.5% of LR4A cancers were detected within 3 months. Conclusions: Modification of the definition and suggested workup of positive and suspicious lung cancer screening findings appears warranted.